San Diego, CA. – February 27, 2018 – Millennium Health, a leading health solutions company, is pleased to announce the appointment of Andrew A. Lukowiak, Ph.D. as Chief Executive Officer (CEO) effective March 1, 2018. Dr. Lukowiak has nearly 20 years of management experience in molecular diagnostics and most recently served as the Chief Operating Officer (COO) and interim-CEO of a privately held precision medicine company, where he had been a part of the management team since 2013.
“On behalf of the Board of Directors and the Company, we are thrilled to have Andrew join Millennium Health as CEO,” said Gene Davis, Chairman of the Board. “He has extensive experience in the industry and the skills to lead a management team focused on profitable growth and an expanding portfolio of products and services.”
Under its genetics brand CogenDx, Millennium Health most recently launched DxWound, a proprietary DNA-based tool that helps clinicians rapidly determine course of therapy for patients with suspected wound infections.
“I’m honored to be joining Millennium’s leadership team at this stage in the Company’s history,” said Lukowiak. “The opportunity to better serve our patients, physicians, and partners by enhancing our existing services and creating complementary verticals in the molecular diagnostics space is incredibly exciting.”
About Andrew A. Lukowiak, Ph.D.
Dr. Lukowiak joins Millennium with almost 20 years of management experience in the molecular diagnostics space. Most recently, Dr. Lukowiak was Chief Operating Officer (COO) and interim-CEO of a commercial stage CLIA laboratory specializing in the combined use of genetics and algorithmic decision support to improve therapeutic outcomes. Prior to joining his previous company, Dr. Lukowiak held key positions at GenMark Diagnostics, Hologic, and Third Wave Technologies where he played a central role in the execution of the company’s clinical strategy; including the development of the first pharmacogenetic test to be cleared by the FDA for use with a specific drug. Dr. Lukowiak has managed a diverse set of departments and functions throughout his career including Operations, R&D, Quality/Regulatory Affairs, Scientific/Clinical Affairs, Customer Service, and Reimbursement. Dr. Lukowiak earned his doctorate in Genetics from the University of Georgia and his bachelor’s degree in Biology from Pennsylvania State University.
About Millennium Health
Millennium Health is transforming the way medications are prescribed by providing accurate, timely and actionable information that helps clinicians optimize treatment decisions for their patients. We offer a suite of services that includes Millennium PGTSM, Millennium UDTSM and Millennium OFTSM. Our genetics brand, CogenDx, offers DxWound and DxSurgical. Millennium Health’s comprehensive health solutions provide Personalized Medication Intelligence. More information can be found at www.millenniumhealth.com.
CogenDx, the genetics brand of Millennium Health, LLC, enables clinicians to personalize treatment decisions for patients using state-of-the-art molecular diagnostic technology. Our portfolio includes DxWound, a proprietary DNA-based tool that helps clinicians rapidly determine course of therapy for patients with suspected wound infections. We also offer DxSurgical, a genetic test that helps predict response to commonly prescribed medications and determine genetic risks underlying certain potential surgical complications. More information can be found at www.cogendx.com.